Best GLP-1 for Weight Loss: Clinical Data & Biomarkers

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The 'best' GLP-1 for weight loss is not universal—it depends on your metabolic profile, baseline health markers, and how your body's GLP-1 signaling pathways are genetically predisposed to respond. Clinical trials show tirzepatide and semaglutide deliver different weight loss magnitudes and tolerability profiles, making personalized evaluation essential.

Patients and providers benefit from understanding not just published efficacy data, but also biomarker context specific to your metabolism. PlexusDx offers a precision-wellness approach: genetic insight into peptide pathway predispositions, combined with clinical evidence review, can support a more informed conversation about which GLP-1 formulation aligns with your individual health profile.

Clinical Efficacy: How Tirzepatide and Semaglutide Compare in Trials

Tirzepatide (a GIP/GLP-1 receptor agonist) demonstrated greater weight loss than semaglutide in head-to-head trials. SURPASS-2 showed tirzepatide users lost 22–25% of baseline body weight over 52 weeks, versus semaglutide users at 14%. This dual-receptor mechanism engages both GLP-1 and GIP pathways, intensifying metabolic effects.

Semaglutide, a GLP-1-only agonist, remains highly effective for many patients. STEP trials documented 15–18% weight loss at maximum doses. The choice between these medications should account for individual tolerability, comorbidities, and baseline metabolic markers—not efficacy alone.

Biomarker and Metabolic Factors That Influence GLP-1 Response

Your fasting glucose, insulin resistance (HOMA-IR), inflammatory markers, and lipid profile can predict how well you'll respond to GLP-1 therapy. Patients with elevated baseline fasting insulin and significant insulin resistance may show stronger metabolic benefit from tirzepatide's dual mechanism. Conversely, those with milder insulin resistance may achieve adequate results with semaglutide at lower cost.

Genetic variants in GLP-1 receptor pathways, GIP receptor genes, and metabolic regulators (FTO, MC4R) influence receptor sensitivity and drug response variability. Assessment of these predispositions, alongside clinical biomarkers, can support provider decision-making before initiating therapy.

Biomarker / Factor	Clinical Significance for GLP-1 Selection
Baseline Fasting Insulin	Higher levels may indicate stronger tirzepatide benefit due to GIP pathway activation
HOMA-IR (Insulin Resistance Index)	HOMA-IR > 3.0 often correlates with dual-agonist responsiveness
HbA1c / Glucose Control	Elevated HbA1c suggests metabolic dysfunction that benefits from GLP-1; baseline level helps dose selection
Triglycerides & Lipid Profile	GLP-1 improves lipids; baseline dyslipidemia supports earlier, more aggressive GLP-1 initiation
GLP-1R and GIPR Genetic Variants	Predisposition variants (rs6923761, rs1800437) may correlate with receptor responsiveness and efficacy variability

Gastrointestinal Tolerability and Individual Response Patterns

Nausea, vomiting, and constipation are common GLP-1 side effects. Tirzepatide users report higher rates of GI events than semaglutide users in trials, though most resolve within weeks. Slow titration schedules, lower initial doses, and dietary adjustments minimize tolerability issues in many patients.

Your genetic predisposition and baseline GI sensitivity matter. Some individuals tolerate rapid escalation; others benefit from extended dose progression. Compounded GLP-1 protocols—such as microdose regimens or gradual titration schedules—offer flexibility to match your tolerance profile while maintaining clinical benefit.

Who Benefits Most and When to Seek Provider Guidance

GLP-1 therapy is appropriate for individuals with a BMI ≥27 with weight-related comorbidities (hypertension, dyslipidemia, prediabetes) or BMI ≥30, and for those with type 2 diabetes. Pregnancy, personal or family history of medullary thyroid cancer, and multiple endocrine neoplasia type 2 are contraindications. A thorough medical history and baseline labs are essential before selection.

Your provider should evaluate your metabolic profile, medication interactions, kidney and liver function, and GI history before recommending semaglutide or tirzepatide. Genetic predisposition testing can complement this assessment by revealing how your peptide pathways are positioned to respond—supporting a truly individualized treatment plan.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your inherent predispositions in GLP-1 signaling pathways (GLP1R rs6923761), GIP receptor function (GIPR rs1800437), and metabolic regulation genes (FTO, MC4R). This insight, combined with your biomarker data, supports a more nuanced conversation with your provider about whether semaglutide or tirzepatide aligns with your metabolic blueprint.

The genetic test reveals predispositions—not guarantees. Variants associated with higher GLP-1 receptor sensitivity, for example, may correlate with stronger efficacy at lower doses, but individual response still varies. Should be interpreted with a qualified healthcare provider alongside clinical labs, weight history, and comorbidity profile.

By understanding both your genetic predispositions and biomarker landscape, you and your provider can make a more informed GLP-1 selection decision. PlexusDx compounded semaglutide (from $179/mo) and tirzepatide (from $229/mo) options offer cost-effective access through licensed 503A pharmacies, paired with the clarity that genetic and biomarker context provides.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.